Assembly Bioscie Stock Price, News & Analysis

Assembly Biosciences, Inc. (ASMB) announced the granting of stock options to three new employees, totaling 25,000 shares at an exercise price of $4.16 per share. This measure is designed to attract talent, with options vesting over four years and subject to continued employment. The options were approved by the Compensation Committee, adhering to Nasdaq Listing Rule 5635(c)(4). Assembly Bio is focused on innovative therapies for hepatitis B virus (HBV), aiming to provide curative solutions to the estimated 270 million people affected globally.

Assembly Biosciences, Inc. (ASMB) reported financial results for Q1 2021, focusing on hepatitis B virus (HBV) therapies. The company initiated two Phase 2 triple combination studies with its lead core inhibitor candidate, vebicorvir (VBR). Financially, cash and equivalents stood at $214.9 million, sufficient to fund operations into 2023. However, revenues fell to $0 due to the wind-down of the microbiome program, while R&D expenses decreased to $18.6 million. The net loss for the quarter was $27.2 million, or $0.69 per share, marginally higher than the previous year.

Assembly Biosciences (Nasdaq: ASMB) announced the grant of stock options to three new employees, totaling 26,000 shares at an exercise price of $5.05 per share. This initiative serves as a material inducement for the new hires to join the company. The options carry a ten-year term and vest over four years, with a quarter vesting on the first anniversary. The grants adhere to Nasdaq Listing Rule 5635(c)(4) and are part of Assembly Bio's 2020 Inducement Award Plan, approved by the Compensation Committee, which comprises only independent directors.

Assembly Biosciences (ASMB) reported its financial results for Q4 and the fiscal year ended December 31, 2020. The company is concentrating on developing finite and curative therapies for chronic hepatitis B, halting Phase 3 studies of vebicorvir as a chronic suppressive treatment. They reported revenues of $79.1 million for 2020, a significant increase from $16.0 million in 2019, largely due to collaborations with BeiGene and Abbvie. R&D expenses rose to $106.8 million, reflecting a growing focus on HBV. The net loss for 2020 was $62.2 million, showing improvement from $97.6 million in 2019.

Assembly Biosciences (ASMB) announced a strategic shift from Phase 3 clinical studies of vebicorvir (VBR) to focus on finite and curative therapies for hepatitis B virus (HBV). This change aims to expedite the development of more potent core inhibitors and novel treatment combinations. The company anticipates extending its cash runway into 2023, bolstered by ongoing clinical studies, including a Phase 2a trial combining VBR with Nucleos(t)ide Analogue Reverse Transcriptase Inhibitors. CEO John McHutchison reaffirms commitment to addressing HBV's unmet medical needs.

Assembly Biosciences (ASMB), a clinical-stage biotechnology firm focused on hepatitis B virus (HBV) therapeutics, announced two investor events. The first is a Key Objectives and Anticipated Progress Conference Call on February 25, 2021, at 5 p.m. ET, coinciding with the release of Q4 and year-end 2020 financial results. The second event is the SVB Leerink 10th Annual Global Healthcare Conference, featuring CEO John McHutchison in a fireside chat on February 26, 2021, at 1:40 p.m. ET. Both events will be accessible via Assembly Bio’s website, with archived webcasts available for replay.

Assembly Biosciences, Inc. (Nasdaq: ASMB) announced the grant of stock options to three new employees, totaling 38,000 shares at an exercise price of $5.79 per share. This incentive is part of the company's strategy to attract talent as they develop therapies targeting hepatitis B virus (HBV). The stock options have a ten-year term and vest over four years. These grants were made under the 2020 Inducement Award Plan and are approved by the Compensation Committee, aligning with Nasdaq Listing Rule 5635(c)(4).

Assembly Biosciences, Inc. (Nasdaq: ASMB) has decided to wind down its microbiome program to concentrate resources on advancing its hepatitis B virus (HBV) therapeutic portfolio. This strategic move aims to enhance the company's focus on developing core inhibitors for chronic HBV treatments. As of September 30, 2020, Assembly Bio reported cash reserves of approximately $238M, projected to sustain operations into the second half of 2022. The decision does not stem from any negative data regarding the microbiome program and is anticipated to conclude by January 31, 2021.

Assembly Biosciences, Inc. (Nasdaq: ASMB), announced the grant of stock options for 14,520 shares to three new employees, with an exercise price of $5.66 per share, based on the closing price on December 1, 2020. The options will vest over four years, with one-fourth vesting after the first year and the remaining in monthly installments. This grant is part of the 2017 Inducement Award Plan and was approved by the Compensation Committee. The new employees do not hold executive positions.